2 terminated, 1 active not recruiting, 1 withdrawn. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow SM-88: new trials by email Literature Review of SM-88 trials Research Report on SM-88
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SM-88 in Advanced Cancers SM-88 - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Tyme, Inc | 2022-10-01 | 2022-07-01 | |
| Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer SM-88 - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Terminated | Georgetown University | 11 | 2021-09-22 | 2023-08-28 |
| SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) - Sarcoma, Ewing, Sarcoma | Phase 2 | Active not recruiting | Sarcoma Oncology Research Center, LLC | 31 | 2020-01-03 | 2025-02-24 |
| A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer SM-88 used with MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, and 5-FU - Pancreatic Cancer | Phase 2 / Phase 3 | Terminated | Tyme, Inc | 130 | 2018-03-27 | 2024-11-06 |
Breast Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (1) · Pancreatic Neoplasms (1) · Sarcoma (1) · Sarcoma, Ewing (1)
Tyme, Inc (2) · Georgetown University (1) · Sarcoma Oncology Research Center, LLC (1)
United States (3)
Giuseppe DelPriore, MD, MPH (1) · Nadia Ashai, MD (1) · Sant P Chawla, MD (1)